Pharming Jumps 21% Before Q3 Print

Pharming Group heads into its October 27 Q3 results on the back of a sharp, unusual rally that has put the stock in a very different position from its peers.

The price action stands out above everything else in the setup. The stock climbed 21% in a week to close at EUR 1.012, a move that puts it roughly 59% below the analyst consensus target of EUR 2.48. That gap is large enough to raise questions about whether the rally is a catch-up trade or something more specific. Correlated peers moved in the opposite direction over the same period: ENGN fell 7.6%, INSM dropped 4.2%, and ALNY slid 2.9%. Pharming is moving against the grain of its own peer group.

The borrow market reflects the speed of that move. Availability tightened sharply, falling from around 145% to 92% over three trading days, the lowest reading in the recent window. The direction is clear: shorts are covering or new buyers are absorbing the available float faster than supply can respond. Cost to borrow remains low at under 1%, so the tightening is a volume phenomenon rather than a sign of any structural scarcity. The ORTEX short score has edged up to 67.8, consistent but not extreme.

The bull and bear debate heading into this print is well-defined. On the positive side, the analyst recommendation score ranks in the 97th percentile across the ORTEX universe, and the stock carries an earnings yield factor in the 76th percentile, signalling a cheap print relative to near-term earnings power. EV/EBITDA has expanded to 14.7x, up more than a full turn on the week, reflecting the move in the stock price. Bears point to the other side of the scorecard: the EPS surprise factor ranks in the 11th percentile, meaning Pharming has a poor recent track record of beating estimates. The last two earnings releases ended badly for holders, with the July 2026 print producing a single-day drop of just over 20%, followed by a further 14% decline across the following five days.

That history sets the stakes plainly. The question the October 27 report will test is whether the 21% pre-earnings rally reflects genuine fundamental improvement, or whether the stock has simply repriced to a level that once again leaves little room for the kind of miss that drove the July outcome.